Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase

Hong-Tao Xu, a Maureen Oliveira, a Peter K. Quashie, a,b Matthew McCallum, a,c Yingshan Han, a Yudong Quan, a Bluma G. Brenner, a and Mark A. Wainberg, a,b,c

McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada, a and Departments of Medicine, b and Microbiology and Immunology, c McGill University, Montreal, Quebec, Canada

The emergence of HIV-1 drug resistance remains a major obstacle in antiviral therapy. M184I/V and E138K are signature mutations of clinical relevance in HIV-1 reverse transcriptase (RT) for the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine (3TC) and emtricitabine (FTC) and the second-generation (new) nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV), respectively, and the E138K mutation has also been shown to be selected by etravirine in cell culture. The E138K mutation was recently shown to compensate for the low enzyme processivity and viral fitness associated with the M184I/V mutations through enhanced deoxynucleoside triphosphate (dNTP) usage, while the M184I/V mutations compensated for defects in polymerization rates associated with the E138K mutations under conditions of high dNTP concentrations. The M184I mutation was also shown to enhance resistance to RPV and ETR when present together with the E138K mutation. These mutual compensatory effects might also enhance transmission rates of viruses containing these two mutations. Therefore, we performed tissue culture studies to investigate the evolutionary dynamics of these viruses. Through experiments in which E138K-containing viruses were selected with 3TC-FTC and in which M184I/V viruses were selected with ETR, we demonstrated that ETR was able to select for the E138K mutation in viruses containing the M184I/V mutations and that the M184I/V mutations consistently emerged when E138K viruses were selected with 3TC-FTC. We also performed biochemical subunit-selective mutational analyses to investigate the impact of the E138K mutation on RT function and interactions with the M184I mutation. We now show that the E138K mutation decreased rates of polymerization, impaired RNase H activity, and conferred ETR resistance through the p51 subunit of RT, while an enhancement of dNTP usage as a result of the simultaneous presence of both mutations E138K and M184I occurred via both subunits.

HIV-1 reverse transcriptase (RT) is crucial for HIV-1 replication and is responsible for converting the single-stranded RNA genome into double-stranded DNA (dsDNA), which becomes integrated into host cell DNA. RT is a multifunctional enzyme that carries out RNA-dependent DNA polymerase (RDDP), DNA-dependent DNA polymerase (DDDP), and RNase H activities (19). HIV-1 RT is a heterodimer composed of p66 (560 amino acid [aa] residues; 66 kDa) and p51 (440 aa residues; 51 kDa). Crystal structure analyses have shown that both subunits contain four common subdomains, designated "fingers" (residues 1 to 85 and 118 to 155), "palm" (residues 86 to 117 and 156 to 236), "thumb" (residues 237 to 318), and "connection" (residues 319 to 426) (30). The nucleic acid binding cleft is formed by the fingers, palm, and thumb subdomains of p66 and the thumb subdomain of p51, which, together with the connection subdomains of both subunits, contributes to the "floor" of the cleft (30, 35). It has been proposed that the p51 subunit simply provides structural support to p66 and does not possess independent enzymatic functions.

Due to its crucial role in the viral replication cycle, HIV-1 RT has been a major target for the development of antiviral therapies. Currently, two classes of RT inhibitors (RTIs) have been approved by multiple regulatory agencies for the treatment of HIV-1 infection, i.e., nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs act by causing chain termination, while NNRTIs act allosterically by binding to the NNRTI binding pocket located 10 Å from the polymerase active site (45). Both NRTIs and NNRTIs are key components of highly active antiretroviral therapy (HAART), but both classes of drugs can be compromised by drug resistance, which, in the case of NNRTIs, is due to mutations within the NNRTI binding pocket, often at p66 amino acid positions 100 to 110, 180 to 190, and 220 to 240, that substantially decrease susceptibility to first-generation (older) NNRTIs such as nevirapine (NVP) and efavirenz (EFV) (22). One major characteristic of the first-generation NNRTIs is that they have a low genetic barrier for resistance, as only a single mutation, such as K103N, is sufficient to confer diminished susceptibility to all first-generation NNRTIs. Two second-generation (newer) NNRTIs, etravirine and rilpivirine (RPV), have recently been approved for use in treatment-experienced patients and in drug-naïve patients, respectively. Distinct from the first-generation NNRTIs, both ETR and RPV generally require an accumulation of several mutations in order for resistance to occur (1, 4). A unique feature of these 2 second-generation NNRTIs is that their innate flexibility allows these compounds to adopt multiple conformations such that potent activity...
can be retained against both wild-type viruses and viruses that are resistant to first-generation NNRTIs (1, 4, 25).

Several data sets on the role that RT mutations may play in regard to resistance against the 2 second-generation NNRTIs ETR and RPV are now available. For ETR, 20 mutations, including V90I, A98G, L100I, K101E/H/P, V106I, E138A/G/K/Q, V179D/F/Y, Y181C/I/V, G190S/A, and M230L, have been identified as resistance-associated mutations (RAMs) (43), while 15 mutations, including K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, and M230I/L, have been recognized as RAMs for RPV (26). However, the degree of resistance conferred by each of these mutations can be variable, and studies on recombinant HIV-1 RT enzymes and HIV-1 infectious clones have demonstrated, for example, that the G190A mutation does not affect susceptibility to ETR (53).

The E138K mutation in HIV-1 RT was recently shown to commonly emerge as the first mutation in cell culture selection experiments with ETR (3) and has also been selected in cultures by RPV (4). The phase III DUET clinical trials on the use of ETR in treatment-experienced HIV-1-infected patients showed that substitutions at position V179 were most common among treatment failures, followed by mutations at position E138, among which the E138G and E138Q mutations, but not the E138K mutation, were frequently observed (46). Recently, phase III clinical trials (ECHO and THRIVE) on the use of the combination of RPV-tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) in drug-naive patients showed that the most frequent mutations to emerge among virological failures were the mutations E138K and M184I, which are responsible for resistance to FTC and RPV, respectively (34). The M184I mutation was also shown to enhance resistance to RPV and ETR when present together with the E138K mutation (21, 31). These results indicate that the E138K mutation is probably a signature mutation for the second-generation NNRTI RPV and that the role of the E138K mutation in resistance to both RPV and ETR should be further investigated.

Our laboratory recently generated recombinant mutated and wild-type (WT) reverse transcriptase enzymes and HIV-1-derived infectious clones containing these mutations and demonstrated that the E138K mutation compensates for the deficit in deoxynucleoside triphosphate (dNTP) usage by the M184I/V mutations and restores both the RT enzymatic processivity and viral replication capacity of HIV-1 variants harboring the M184I/V mutations (54). The compensatory effect of the M184I/V mutations may have clinical significance in regard to treatment failures involving ETR-RPV as well as the possible presence of these mutations in transmitted resistance. Mutual compensatory fitness was also demonstrated by sensitive growth competition assays involving the E138K and M184I/V mutations (21).

Although viral fitness is one important parameter that determines the evolutionary dynamics of HIV-1-resistant mutants, other factors such as the number of available target cells and mutation or recombination rates can also have impact. In view of the high prevalence of M184I/V mutations due to the clinical use of lamivudine (3TC) and FTC, we wondered why the E138K mutation had not been seen over time in patients who failed 3TC- and/or FTC-based therapies, as might have been expected due to the compensatory effects that we and others have described (21, 54). Obvious questions are whether the pressure of the M184I/V mutations might somehow prevent the emergence of the E138K mutation and whether the E138K mutation might impact the evolutionary dynamics of M184I/V-containing viruses under 3TC-FTC selection pressure. Also, how will different cell types with different dNTP pools respond to drug selection pressure? This study addresses these issues.

In addition, we recently demonstrated that recombinant HIV-1 RT enzymes containing the E138K mutation are impaired in RNase H activity and have decreased polymerization rates under conditions of high dNTP concentrations (54). While RTs containing either the M184V or M184I mutation, associated with resistance to 3TC and FTC, are impaired in the usage of dNTPs (6, 15, 18), the simultaneous presence of the E138K mutation together with either the M184V or M184I mutation can compensate for this deficit in dNTP usage at low dNTP concentrations through the promotion of tighter dNTP binding. These results indicate that the E138K mutation may also play an important role in the fine-tuning of RT activity. E138 is part of the β7-β8 loop in the p51 subunit at the p66/p51 interface, which is a key structural element for RT dimerization and constitutes the floor of the NNRTI binding pocket (17, 39, 40, 42). Although others have previously described the E138K mutation and have shown that this mutation confers resistance to the [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′(4′-amino-1′,2′-oxathiole-2′,2′-dioxide)]-β-D-2-pentofuranosyl (TSAO) family of NNRTIs though the p51 subunit (8, 11), it is still unclear whether the E138K mutation acts in a subunit-specific fashion to impact RT catalytic activities (both polymerase and RNase H) and resistance to second-generation NNRTIs and whether the compensatory effects with the M184I mutation also depend on the presence of the E138K mutation within p51. In the present study, we used subunit-selective mutagenesis to characterize recombinant RT enzymes containing the E138K mutation in either the p66 subunit (p51WT/p66E138K), the p51 subunit (p51E138K/p66WT), or both subunits (p51E138K/p66E138K) and have now demonstrated that ETR resistance, the impairment of RNase H cleavage, and decreased RT polymerization rates are all conferred by the presence of the E138K mutation within the p51 subunit. In contrast, the presence of the E138K mutation within both p51 and p66 is required for the compensatory effects that are mediated by both the E138K and M184I mutations in tandem.

**MATERIALS AND METHODS**

**Chemicals, cells, viruses, and nucleic acids.** Etravirine was a gift of Tibotec (Titusville, NJ), pRT6H-PROT, pRT, and pRT6H51 plasmid DNAs were kindly provided by Stuart F. J. Le Grice, National Institutes of Health, Bethesda, MD.

Cord blood mononuclear cells (CBMCs) were obtained through the Department of Obstetrics, Jewish General Hospital, Montreal, Canada. MT2 cells were obtained from the NIH AIDS Research and Reference Reagent Program. HEK293T cells were obtained from the American Type Culture Collection (ATCC).

HIV-1-derived viral clones containing the desired mutations were made as described previously (55). Briefly, fragments spanning RT amino acids 25 to 314 from MscI and PflMI digestion from the RT expression plasmid DNAs harboring the corresponding mutations described below were used to replace the corresponding fragment of plNL4.3PB proviral DNA (23). Wild-type and mutant viruses were generated by the transfection of proviral plasmid DNAs into HEK293T cells, as described previously, using Lipofectamine 2000 (Invitrogen, Burlington, Ontario, Canada) (35).

A 497-nucleotide (nt) HIV-1 primer binding site (PBS) RNA template spanning the 5′ untranslated region (UTR) to the PBS was transcribed in vitro from Accl-linearized pHIV-PBS DNA (2) by using a T7-
MEGAshortscript kit (Ambion, Austin, TX) as described previously (56). The oligonucleotides used in this study were synthesized by Integrated DNA Technologies Inc. (Coralville, IA) and purified by polyacrylamide-urea gel electrophoresis.

Selection of HIV-1 mutants in MT2 cells and CBMCs under drug selection pressure. MT2 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine per milliliter, 100 U of penicillin per milliliter, and 100 µg of streptomycin per milliliter. Cord blood mononuclear cells (CBMCs) stimulated by phytohemagglutinin A (PHA) were cultured in 10% RPMI 1640 medium supplemented with 10% qualified FBS, 20 U of human interleukin-2 (IL-2)/ml, 5 µg of hydrocortisone/ml, 2 mM L-glutamine/ml, 100 U of penicillin/ml, and 100 µg of streptomycin/ml. Cells in 24-well tissue culture plates were infected with recombinant viral clones at a similar multiplicity of infection (MOI). Selection for viral resistance mutations was performed by using increasing concentrations of RT inhibitors at starting concentrations below the 50% effective concentration (EC50), as described previously (3, 38). As controls, all viruses were simultaneously passaged without drugs. Virus-containing culture media were harvested and kept at −80°C for subsequent standard genotypic analyses. Selections for resistance were performed over 9 weeks and 19 weeks for MT2 cells and CBMCs, respectively.

Recombinant reverse transcriptase expression and purification. The p51 and p66 sequences of RT were amplified by PCR from pNL4.3-derived infectious clones (55) and cloned into the pcRSFDuet-1 vector (Novagen) and the pcCDFDuet-1 vector (Novagen), respectively, using Ncol and Sall restriction sites for both subunits. Sequences coding for a hexahistidine (His6) tag were added at the N terminus of p51. There was no tag added to either terminus of the p66 subunit. To produce mutant RT, mutations were introduced into specific subunits by using the QuikChange mutagenesis kit (Agilent Technologies Canada Inc., Mississauga, Ontario, Canada). DNA sequencing was performed across the RT coding region to verify the absence of spurious mutations and the presence of desired mutations. RT enzymes were expressed in Escherichia coli BL21 cells (Invitrogen, Burlington, Ontario, Canada) and purified by nickel affinity chromatography and Q Sepharose ion-exchange chromatography, as described previously (33). The polymerase activity of each recombinant RT enzyme preparation was evaluated in triplicate by using the synthetic homopolymeric poly(rA)/p(dT)12–18 template/primer (T/P) (Midland Certified Reagent Company) as described previously (41). An active unit of RT was defined as the amount of enzyme that incorporates 1 pmol of dTTP in 10 min at 37°C.

RT inhibitor susceptibility assays. Susceptibility to ETR was assayed by using recombinant RT enzymes and a heterodimeric HIV-1 PBS RNA T/P system as described previously (56). Briefly, RT reaction buffer containing 50 mM Tris-HCl (pH 7.8), 6 mM MgCl2, 60 mM KCl, and dNTPs (5 µM each) with 2.5 µCi of [3H]dTTP (70 to 80 mCi/µmol), 30 nM heterogeneous HIV-1 RNA template/primer, the same activity of RT enzymes, and variable amounts of RT inhibitors were included in 50-µl reaction volumes. In the reaction mixtures, the final concentrations of dNTPs were 1 mM each, and dNTPs were mixed with 2 volumes of stop solution (95% formamide, 10 mM EDTA, and 0.1% each of xylene cyanol and bromophenol blue) were then added to stop the reaction. Reaction products were denatured by heating at 95°C and analyzed by liquid scintillation spectrometry using a Perkin-Elmer 1450 MicroBeta TriLux microplate scintillation and luminescence counter. The steady-state kinetic parameter Ks for nucleotide substrates was determined by nonlinear regression analysis using GraphPad Prism5.01 software.

RT-catalyzed RNase H activity. RNase H activity was assayed by using a 41-mer 5′-[32P]-labeled heteropolymeric RNA template, kim32D at a 1:4 molar ratio, as described previously (54). Reactions were conducted at 37°C with mixtures containing an RNA-DNA duplex substrate (20 nM) with RT enzymes (~200 nM) in assay buffer (50 mM Tris-HCl [pH 7.8], 60 mM KCl, 5 mM MgCl2) in the presence of a heparin trap (2 mg/ml). Aliquots were removed at different time points after the initiation of reactions and quenched by using an equal volume of formamide sample loading buffer (96% formamide, 0.1% each bromophenol blue and xylene cyanol FF, and 20 mM EDTA). The samples were heated to 90°C for 3 min, cooled on ice, and electrophoresed through 6% polyacrylamide–7 M urea gels. The gels were analyzed by phosphorimaging. The efficacy of the heparin trap was verified by preincubation experiments performed by a 10-min preincubation of enzymes with the substrate and various concentrations of the heparin trap, followed by the initiation of RNase H activity in the presence of magnesium (see below).

RNA-dependent DNA polymerase activity. The same 497-nt RNA and 5′-end 32P-labeled D25 primers described previously (54) were used to assess the polymerization rates of recombinant RT enzymes in time course experiments. Final reaction mixtures contained 20 nM T/P, 400 nM RT enzyme, 50 mM Tris-HCl (pH 7.8), and 30 mM NaCl. Reactions were initiated by the addition of 6 mM MgCl2 and dNTPs at 200 µM to the mixtures, and the mixtures were sampled at 30 s and 60 s, respectively, and mixed with 2 volumes of stop solution. Reaction products were separated by 6% denaturing polyacrylamide gel electrophoresis and analyzed as described previously (54).

Processivity assays. The processivity of recombinant RT proteins was analyzed as described previously, using a heteropolymeric RNA template in the presence of a heparin enzyme trap to ensure a single processive cycle, i.e., a single round of binding and of primer extension and dissociation (54). The T/P was prepared by annealing the 497-nt HIV PBS RNA with the 32P-5′-end-labeled 25-nt DNA primer D25 at a molar ratio of 1:1, denatured at 85°C for 5 min, and then slowly cooled to 55°C for 8 min and 37°C for 5 min to allow the specific annealing of the primer to the template. RT enzymes with equal amounts of activity and 40 nM T/P were preincubated for 5 min at 37°C in a buffer containing 50 mM Tris-HCl (pH 7.8), 50 mM NaCl, and 6 mM MgCl2. Reactions were initiated by the addition of dNTPs at 0.5 µM and a heparin trap (final concentration, 3.2 mg/ml) to the mixtures, and the mixtures were incubated at 37°C for 30 min; 2 volumes of stop solution (90% formamide, 10 mM EDTA, and 0.1% each of xylene cyanol and bromophenol blue) were then added to stop the reaction. Reaction products were denatured by heating at 95°C and analyzed by using 6% denaturing polyacrylamide gel electrophoresis and phosphorimaging. The effectiveness of the heparin trap was verified in control reactions in which the trap was preincubated with a substrate before the addition of RT enzymes and dNTP.

Analysis of steady-state kinetics. Kinetics studies were carried out by a modification of a previously described method using homopolymeric poly(rA)/p(dT)12–18 and complementary dTTP as the nucleotide substrate (54). The reaction mixture (10 µl) contained 50 mM Tris-HCl (pH 7.8), 60 mM KCl, 6 mM MgCl2, 5 mM dithiothreitol (DTT), 0.5 U/ml poly(rA)/p(dT)12–18, RT enzymes, variable concentrations of the tracer [3H]dTTP, and cold dTTP (0.2 to 200 µM). Reactions were run at 37°C and quenched by the addition of 0.2 ml of 10% cold trichloroacetic acid and 20 mM sodium pyrophosphate to the mixtures; products were fractionated on a Millipore 96-well MultiScreen HTS FC filter plate and measured by liquid scintillation spectrometry using a Packard Trilux microplate scintillation and luminescence counter. The steady-state kinetic parameter Ks for nucleotide substrates was determined by nonlinear regression analysis of the substrate concentration and initial velocity data using the Michaelis-Menten equation with the program GraphPad Prism5.01 according to the manufacturer’s instructions.

Downloaded from http://jvi.asm.org/ on July 5, 2017 by guest
RESULTS
Evolution of HIV-1 mutants selected in MT2 cells and CBMCs under drug pressure. It is well known that HIV-1 harboring the M184I/V mutations has a low viral fitness because of deficient dNTP usage, especially in cell types with low dNTP pools. We recently demonstrated that the E138K mutation improved dNTP binding and compensated for the deficit in dNTP usage associated with the M184I/V mutations. Intracellular dNTP pools may impact the evolution of resistant variants, and MT2 cells contain inherently higher concentrations of natural dNTPs than primary cells such as cord blood mononuclear cells (CBMCs). We therefore studied these two different cell types in selection experiments to investigate whether they impact the evolutionary dynamics of viruses containing the E138K or M184I/V substitutions (Table 1).

When recombinant HIV-1 containing the E138K mutation was selected with 3TC or FTC, it was observed that the M184I mutation emerged in MT2 cells in almost all cases, while the M184V mutation was selected in CBMCs. In the case of M184I/V viruses selected with ETR, the E138K mutation emerged in almost all cases. These selections were performed on at least three different occasions, with similar results being obtained each time. These results indicate that the presence of the M184I/V mutations does not prevent the emergence of the E138K mutation, nor does the presence of the E138K mutation prevent the emergence of the M184I/V mutations. The more frequent presence of the M184V mutation in CBMCs may be due to a higher dNTP usage than that with the M184I mutation, which is more impaired in dNTP usage than the M184V mutation. Interestingly, WT viruses grown in MT2 cells did not develop the E138K mutation under ETR pressure but instead developed the E138G/Q mutation, whereas the E138K mutation was consistently selected under ETR pressure in CBMCs. These differences might also result from different dNTP pool sizes in the two cell types.

Purification of recombinant HIV-1 heterodimeric RT enzyme. We purified reconstituted RT heterodimers after separately expressing each subunit by the cotransformation of E. coli with two individual plasmid DNAs. The recombinant WT RT heterodimer (p66/p51) and RT enzymes containing the E138K mutation in either or both subunits were purified to $>95\%$ homogeneity; the RT p66 and p51 subunits were purified at similar molar ratios based on SDS-PAGE analysis (Fig. 1A), showing that the mutations introduced did not interfere with either heterodimer formation or enzyme purification. No significant differences in specific activity were observed among the purified mutant RT enzymes compared to WT RT (Fig. 1B). We have found that this system produces more efficient yields in our hands than the use of M15 bacterial cells (20).

One concern is that the p66 subunit of RT is highly susceptible to proteolysis, which could yield a p51-like subunit (p51*) that does not contain the His$_6$ tag and thus does not bind to Ni-nitrilotriacetic acid (NTA) resin. However, the attachment of the His$_6$ tag to the C terminus of p66 could result in a situation in which p51*/p66-His$_6$ might be purified and p51* would not contain the desired mutation. With our procedure, it is possible that trace amounts of a His$_6$-p51/p51* homodimer might be purified, but this His$_6$-p51/p51* would not be as enzymatically active as heterodimeric RT enzymes. The intact p66 subunits in our RT heterodimer purifications were verified by SDS-PAGE (Fig. 1).

The E138K mutation in HIV-1 RT confers ETR resistance through the p51 subunit. To clarify whether the E138K mutation confers resistance to ETR in a subunit-specific fashion, similar to that shown for the TSAO compounds, we performed cell-free

![FIG 1](http://jvi.asm.org/) Purification of recombinant HIV-1 RTs. (A) Coomassie brilliant blue staining of purified heterodimeric RTs following 8% SDS-PAGE. The purifications of heterodimeric RT enzymes was achieved by the attachment of a His$_6$ tag at the N terminus of the p51 subunit through immobilized metal affinity chromatography (IMAC). MW, molecular weight standards (in thousands). Lanes: 1, p66WT/p51WT; 2, p66E138K/p51E138K; 3, p66WT/p51E138K; 4, p66E138K/p51WT; 5, p66E138K-M230M/p51WT; 6, p66E138K-M230M/p51E138K; 7, p66E138K/p51E138K; 8, p66E138K/p51L100I. The positions of purified recombinant RT heterodimers are indicated on the right. (B) Comparison of specific activities of recombinant subunit-selective mutant RT enzymes relative to that of the WT enzyme. DNA polymerase activity was assessed as described in Materials and Methods. Data from a representative experiment performed in triplicate are shown as means ± standard deviations.
The E138K mutation in HIV-1 RT decreases the rate of polymerization through the p51 subunit. Previously, we performed RNA-dependent DNA polymerase reactions using recombinant RT enzymes containing E138K mutations and measured the rates of DNA polymerization at both low and high dNTP concentrations. We found that the E138K mutation caused a decrease in the polymerization rate only at high dNTP concentrations (54). Now, we wished to determine whether the E138K mutation in RT impairs polymerization in a subunit-specific manner and therefore performed RNA-dependent DNA polymerase reactions in time course experiments, as described previously (54), for 30 s and 60 s using the recombinant RT enzymes p66WT/p51WT, p66E138K/p51WT and p66WT/p51E138K (Fig. 3). RT molecules were used at a ~20-fold excess over the substrate so that any RTs that dissociated from the primer terminus during synthesis would be rapidly replaced and also so that the rate-limiting step would be nucleotide incorporation (18). Polymerase reactions were carried out at high dNTP concentrations (200 μM). The rate of polymerization was calculated as the number of nucleotide additions divided by the reaction time, and the longest extension products generated after

![FIG 2 Subunit-specific analysis of the effect of the E138K mutation in HIV-1 RT on RNase H activity.](http://jvi.asm.org/figure/fig2a.png)

**TABLE 2 Susceptibilities to etravirine of WT and mutant RTs harboring the E138K mutation in different RT subunits**

<table>
<thead>
<tr>
<th>RT enzyme</th>
<th>Mean IC₅₀ ± SD (nM)</th>
<th>Fold change in resistance&lt;br&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>p66WT/p51WT</td>
<td>186 ± 15</td>
<td>1.1</td>
</tr>
<tr>
<td>p66E138K/p51WT</td>
<td>669 ± 29</td>
<td>3.6</td>
</tr>
<tr>
<td>p66WT/p51E138K</td>
<td>651 ± 34</td>
<td>3.5</td>
</tr>
<tr>
<td>p66E138K/p51WT</td>
<td>204 ± 20</td>
<td>1.1</td>
</tr>
</tbody>
</table>

*The IC₅₀ (50% drug inhibitory concentration) values were determined by recombinant RT assays. Data represent the mean ± standard deviations of data from 3 independent experiments.*

*Values represent the fold changes in IC₅₀ values for mutated RTs compared to WT RT.*
We performed our gel-based polymerization rate experiments with different batches of purified enzymes and consistently obtained the same results. Differences in polymerization rates were clearly demonstrated by the maximal sizes of the extended products in the gel-based assays and are in good agreement with our previously reported results (56) and those of others (19); however, it would be difficult to conduct analyses of statistical significance in regard to these results. These data do confirm that the E138K mutation decreases the rate of polymerization through the p51 subunit, and this is the first demonstration that an amino acid residue in the p51 subunit can directly impair the polymerization rate of HIV-1 RT. Crystallization of subunit-specific RT E138K enzymes will help to clarify the mechanisms involved, and such studies are under way.

In our assay, RT molecules were in a ~20-fold excess over the substrate so that any RTs that dissociated from the primer terminus during synthesis would be rapidly replaced. Under these conditions, the nucleotide addition, instead of RT dissociation, should be rate limiting. We used an RNA template derived from the 5’ end of the HIV-1 RNA genome containing the PBS; thus, the lower polymerization rates measured in our multiple-turnover experiment than the rates of polymerization usually detected in pre-steady-state single-turnover experiments are due to multiple pauses during DNA synthesis, which greatly lower the average rate of primer extension (28). The same rationale justifies the choice of 30-s and 60-s time points rather than earlier time points, since only very little DNA product was detected in the gel-based assay at such earlier times.

The E138K mutation compensates for M184I-mediated deficits in dNTP usage and restores enzyme processivity via both subunits. The E138K mutation compensates for M184I/V-mediated deficits in dNTP usage and restores enzyme processivity at low dNTP concentrations, thereby restoring a high replication capacity to viruses that possess combinations of the E138K mutation together with the M184I or M184V mutation (54). M184I/V RT is known to have lower enzyme processivity than WT RT, especially at low dNTP concentrations (6, 15, 48), and the M184I mutation is even more impaired than the M184V mutation in regard to processivity (18, 24). Deficits of M184I/V RT in processivity and enzyme activity may be attributable to defective dNTP utilization (15, 18, 24, 48, 51). Now, we wished to investigate whether the compensatory effect of the E138K mutation on the M184I mutation might also be subunit specific, and accordingly, we performed single-cycle processivity assays at low dNTP concentrations with the recombinant RT enzymes p66 WT/p51 WT, p66 M184I/p51 WT, p66 M184I/p51 E138K, p66 M184I E138K/p51 WT, and p66 M184I E138K/p51 E138K (Fig. 4). The results show that the E138K mutation was unable to restore the impaired processivity associated with the M184I mutation when the former mutation was present solely in the p66 or p51 subunit of HIV-1 RT, i.e., p66 M184I/p51 WT and p66 M184I/p51 E138K. In contrast, enzyme processivity was restored when the E138K mutation was present in both p66 and p51, i.e., p66 M184I E138K/p51 WT and p66 M184I E138K/p51 E138K. These results indicate that the E138K mutation restores the enzyme processivity of the M184I mutation via both subunits.

Previous steady-state kinetic studies demonstrated that the E138K mutation resulted in decreased $K_m$ values for dTTP (54). Structural modeling also showed that the addition of the E138K mutation to the M184I/V mutations promoted tighter dNTP binding (54). In the present study, we also performed steady-state
kinetic assays using subunit-selective mutant RT enzymes to investigate the subunit-specific effects of the E138K mutation on dNTP usage (Table 3). When the E138K and M184I mutations were jointly present in p66, RT (p66E138K/M184I/p51WT) had higher $K_m$ values (1.8-fold) for dTTP than WT RT (p66WT/p51WT), but behaved similarly to M184I RT (p66M184I/p51WT) (2.2-fold). RT p66/M184I/p51E138K behaved similarly to p66M184I/p51WT. In contrast, the presence of the E138K mutation in both subunits led to RT (p66E138K/M184I/p51E138K) having a $K_m$ value (1.1-fold) for dTTP similar to that of WT RT (p66WT/p51WT). These results are in agreement with processivity results indicating that the E138K mutation enhances the dNTP affinity through both subunits (16).

**DISCUSSION**

HIV-1 drug resistance mutations are associated with anti-HIV therapy and can be the cause of treatment failure. However, drug-resistant viruses are usually less fit than WT viruses, which can affect the detectability of drug resistance mutations in transmitted resistance. The M184I/V mutations are associated with high-level resistance to 3TC and FTC and are common in treatment failures. The M184I/V mutations are also associated with decreased dNTP usage and have a strong negative impact on viral replication fitness (5, 6, 14, 15, 18, 24, 50). Under selection pressure with 3TC or FTC, both in vitro and in vivo, the M184I mutation usually emerges first and is rapidly replaced by the M184V mutation due to the relative fitness advantage of the latter over the former mutation (13, 15, 29, 48). However, M184I/V mutations are rarely found in cases of transmitted drug resistance (TDR), although the M184V mutation can be detected in newly infected individuals with detection methods that are more sensitive than standard genotyping (12, 47, 52). As a consequence of low viral fitness, the prevalence of the M184V mutation as a single mutation in newly infected individuals wanes over time (52). However, the E138K mutation, which is an important mutation for the second-generation NNRTIs ETR and RPV, can compensate for this deficit in dNTP usage and restore enzyme processivity and viral fitness (54). Although the E138K mutation alone is associated with an impaired polymerization rate and low viral fitness, the M184I/V mutations can also compensate for this deficit (54). We believe that these mutual compensatory interactions between the E138K and M184I/V mutations are clinically relevant in treatment failures involving 3TC-FTC and ETR-RPV and may also be of importance for the potential transmission of drug-resistant HIV-1 variants. Our current findings demonstrate that the M184I/V and E138K mutations can be selected in viruses containing either of these mutations individually under appropriate drug selective pressure in cell types containing high or low dNTP pools.

The transmission of HIV-1 resistance mutations is driven by the treatment rate, the rate of development of acquired resistance, and the fitness of the drug-resistant viruses that emerge (9, 10). Intracellular dNTP pools play an important role in impacting HIV-1 replication kinetics and mutation rates (6, 7, 24, 27, 36, 37). The cellular dNTP concentrations of two different types of HIV-1 target cells, activated/dividing CD4+ T cells and terminally differentiated/nondividing macrophages, were recently determined, and the latter cells contain very low dNTP concentrations (16). Among cells frequently used to cultivate HIV-1 in vitro, the dNTP levels are ~20-fold higher in established T cell lines than in primary peripheral blood mononuclear cells (6). The replication deficit of the M184I/V mutations is detectable only in cells with low dNTP pools (6, 24); in cells with high dNTP pools, the replication rates of these mutated viruses are comparable to those of the wild-type virus. Viruses containing the M184I mutation are more impacted than those containing the M184V mutation, due to a more severe impairment in dNTP usage by RT. However, the M184I mutation is the result of a G→A hypermutation, in comparison to A→G, which yields the M184V mutation, and therefore, the

**TABLE 3 Kinetic parameters of recombinant RT enzymes as determined by analysis of steady-state kinetics**

<table>
<thead>
<tr>
<th>RT</th>
<th>Avg $k_{cat}$ (min⁻¹) ± SD</th>
<th>Avg $K_m$ (μM) ± SD (fold change)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p66WT/p51WT</td>
<td>14.2 ± 1.3</td>
<td>4.89 ± 0.3 (1)</td>
</tr>
<tr>
<td>p66M184I/p51WT</td>
<td>18.4 ± 1.2</td>
<td>10.8 ± 0.7 (2.2)</td>
</tr>
<tr>
<td>p66E138K/p51E138K</td>
<td>17.0 ± 1.6</td>
<td>9.8 ± 0.9 (2.0)</td>
</tr>
<tr>
<td>p66E138K/p51V</td>
<td>17.0 ± 1.4</td>
<td>8.7 ± 0.5 (1.8)</td>
</tr>
<tr>
<td>p66E138K/M184I/p51E138K</td>
<td>16.6 ± 1.6</td>
<td>5.22 ± 0.4 (1.1)</td>
</tr>
</tbody>
</table>

* The steady-state kinetic parameters $k_{cat}$ and $K_m$ for dTTP of WT HIV-1 RT and its mutant derivatives were measured by using poly(rA)/poly(dt)24/14 template/primer. The recombinant RT enzymes were purified in a heterodimeric form, and mutations were introduced into specific subunits. Values are averages ± standard deviations from representative experiments performed in triplicate.

* Fold changes of the $K_m$ values of mutant RT variants compared to the WT.
M184I mutation is usually present before the M184V mutation. The M184V mutation, although clearly less fit than the wild type, is more fit than the M184I mutation and rapidly outgrows the former in vivo (29). Our selection experiments using WT viruses show that the M184I mutation was consistently selected under 3TC-FTC pressure in MT2 cells, which have high dNTP concentrations, whereas the M184V mutation was more often selected in CBMCs, which have lower dNTP concentrations, confirming that differences in dNTP usage can contribute to the differential selection of these two mutations (5, 6, 24, 54). This notwithstanding, it cannot be excluded that the metabolism of 3TC and FTC in the different cells used may have influenced mutational selection. Although we did not measure dNTP concentrations in the cells employed in our study, others have shown previously that dNTP levels are ~20-fold higher in established T cell lines than in primary peripheral blood mononuclear cells (6). The presence of the E138K mutation does not change the evolutionary pattern in either cell type, indicating that the E138K mutation cannot prevent the emergence of the M184I/V mutations under 3TC-FTC pressure.

We also investigated whether the M184I/V mutations can prevent the emergence of the E138K mutation under ETR selection. In CBMCs, the E138K mutation was consistently selected under ETR pressure using both M184I and M184V clonal variants. In contrast, the E138G/Q mutations were selected in MT2 cells under similar circumstances, instead of the E138K mutation. It is not known whether such differences may be attributable to enhanced dNTP usage and a higher processivity associated with the E138K mutation. This is even true in comparison with WT RT under conditions of low dNTP concentrations (54), which makes the HIV-1 E138K mutant more replication competent in cells with low dNTP pools.

Genotyping at various time points after the application of FTC pressure showed that there were no mutations at week 10 and a mixture of M184I/M/V mutations at week 13 and that the M184V mutation was fully represented by week 19. With 3TC pressure, there were no mutations at week 7, a mixture of M184I/M/V mutations at week 10, and the M184V mutation alone at week 13. Previous experiments have indicated that the M184V mutation prevails in MT2 cell culture selections, if drug pressure is continued with either 3TC or FTC (data not shown).

The compensatory effect between the E138K and M184I mutations in enhancing dNTP usage may also stabilize the M184I mutation in CBMCs. The WT virus did not generate the E138K mutation in MT2 cells, which may also be related to the dNTP pool imbalance, since changing the intracellular dCTP/dTTP ratio can alter the evolutionary pattern at E138 under TSAO pressure (7). Possibly, the different sizes of intracellular dNTP pools in MT2 cells and CBMCs also impact the dNTP imbalance bias. The differences among the cell types studied here in regard to dNTP levels may have contributed to differences in results obtained by our group and other groups in regard to considerations of viral fitness among viruses harboring both the M184I and E138K mutations when grown in different cell types (31, 54). Our selection data clearly show that the E138K and M184I/V mutations can be mutually favored in evolution under appropriate selection pressure. It may be anticipated that the increased use of second-generation NNRTIs such as ETR and RPV will lead to a greater selection of E138K mutations in the future. It is therefore relevant to ask whether the E138K mutation may enhance the transmission rates of detectable M184I/V mutations, and methods more sensitive than classical genotyping may be necessary to provide an answer. To try to shed further light on these topics, we have also performed biochemical analyses of RT molecules containing the above-described mutations.

Previous studies have shown that the β7-β8 loop spanning amino acids 133 to 140 of the HIV-1 RT p51 subunit participates in forming the floor of the NNRTI binding platform in the RT crystal structure (17) and helps to maintain the stable, functional heterodimeric enzyme (39, 40, 49). Subunit-selective mutagenesis also showed that the E138K mutation confers resistance to TSAO compounds through the p51 subunit (8, 11); however, no experimental data have been available until now in regard to second-generation NNRTIs. The present study on the use of subunit-selective E138K mutants provides the first enzymatic analysis to confirm that the E138K mutation confers resistance to ETR through the p51 subunit and also shows that E138 in the p51 subunit is directly involved in regulating RNase H processing activity and RT polymerization. We also provide evidence that the E138K mutation compensates for M184I-mediated deficits in dNTP usage through both RT subunits. Our claim that the E138K mutation compensates for M184I-mediated deficits in dNTP usage and restores enzyme processivity via both subunits is based on both Km changes and data from the gel-based processivity assay.

The p51 subunit has been shown to have a critical role in the fine-tuning of HIV-1 RT RNase H activity. Recently, subunit-specific analyses showed that the decreased RNase H activity conferred by the N348I mutation mapped to the p51 subunit (44, 57). We have now extended our previous results (54) to show that the E138 residue in the β7-β8 loop of the p51 subunit also plays a key role in regulating the RNase H processing activity. The decreased RNase H activity associated with the E138K mutation together with a lower rate of polymerization help to explain the lower replication capacity of the E138K virus. Our data on RNase H activity were generated under processive conditions so as to demonstrate the effect of subunit–specific mutations on RNase H cleavage activity alone and not on enzyme-substrate reassociations. In the virion, more RT molecules than RNA genomes are present, thus ensuring that RNase H cleavage can proceed as long as the virus is still replication competent, even though a mutation of interest may diminish RNase H activity. Our finding that the E138K mutation also diminishes the RT polymerization rate is the first evidence that p51 is also involved in the regulation of polymerase activity. It is interesting that the E138K mutation compensates for the M184I-mediated deficit in dNTP usage via both subunits.

Hydrogen exchange mass spectrometry of the p66/p51 RT heterodimer showed that the binding of EFV to the p66 subunit could cause an extensive allosteric change in the p51 subunit as well (19). This example of allosteric subunit cross talk complements our in silico analysis, which suggests that the E138K mutation in p51 causes allosteric changes in the p66 subunit. This also helps to elucidate how the E138K mutation, when located within p51, can affect RNase H activity, even though the E138K mutation is remote from the active site of RNase H. The impact of the E138K mutation on dNTP usage might also occur, in part, through allosteric changes in the p66/p51 heterodimer. The position of the E138K mutation within p51 can also impact the functions of other drug resistance mutations located within p66. Although certain mutational interactions are difficult to predict and have come to light only as a result of the ECHO and THRIVE clinical trials, it
now seems likely that future drug development may need to consider the possibility of unforeseen mutational interactions that may have adverse consequences. As an example, the potential sexual transmission of replication-competent multiply drug-resistant viruses containing both the E138K and M184I mutations could have adverse implications for public health. It will also be important to develop new NNRTIs that retain activity against E138K-containing viruses.

One question that remains is why patients who developed the M184I/V mutations have not also spontaneously generated the E138K mutation, if, indeed, the simultaneous presence of the latter is associated with a restoration of replication competence. A search of multiple clinical databases has failed to reveal evidence of the presence of the E138K mutation in individuals who developed M184I/V mutations (not shown), and our results clearly show that viruses that contain the M184I/V mutations can be selected with ETR to yield the E138K substitution. Perhaps other mutations that are selected by antiretroviral drugs (ARVs) in the clinic, including some in the connection and RNase H domains, may be able to prevent the generation of the E138K mutation. In addition, we have never witnessed the spontaneous emergence of the E138K mutation in M184I/V clonal viruses that have been grown over periods of many months in either the presence or the absence of 3TC. A more common occurrence is a reversion of the M184I/V mutation to WT M184, followed by the more rapid growth of the WT M184-containing virus. The basis for the bias against the spontaneous selection of the E138K mutation by M184I/V-containing viruses in the clinic will require further investigation.

In summary, we have determined that the activities of the E138K mutation to confer ETR resistance, impair RNase H activity, and decrease the RT polymerization rate all occur through the p51 subunit, while the enhancement of dNTP usage in the context of the M184I mutation results from the involvement of both subunits. In addition to providing structural integrity for the p51/p66 heterodimer, p51 is also important for determining rates of polymerization, RNase H processing, and drug resistance. The compensatory effect between the E138K and M184I/V mutations may have clinical significance in regard to treatment failures involving ETR-RPV as well as the detectability of these mutations in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040–4049.

ACKNOWLEDGMENTS

This work was supported by research grants from the Canadian Institutes of Health Research (CIHR).

We thank Stuart F. J. Le Grice for providing HIV-1 RT expression DNAs prT6H-PROT, prT, and p6H51 and Tomozumi Imamichi for pNL4.3FPB plasmid DNA.

We have no conflicts of interest to declare.

REFERENCES


